News | April 28, 2026
Jagsonpal Pharma profit surges 31% in Q4
Rs. 40 cr buyback, 200% dividend announced
Rs. 40 cr buyback, 200% dividend announced
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Growth was broad-based across segments
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Pharma giant targets new standards of care
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
The national platform brought together healthcare professionals, patient advocates, and stakeholders
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
Subscribe To Our Newsletter & Stay Updated
